Three years into a foremost public-private venture between Fiocuz and GlaxoSmithKline, Brazil's main health institute, the company assesses technology transfer and joint research under the deal. GSK was selling off its Synflorix vaccine (in relation to pediatric pneumonia) at some stated prices even as it transferred the technology and the know-how to the Brazil for the eventual national production.
At precisely similar time, GSK was co sponsoring research with the Brazilian government into a new vaccine for Dengue fever. GSK's management must consider whether the PPP provides tactical advantage to its consumer healthcare businesses in Brazil and to access other emerging markets in addition to the threats introduced by the competitive product obsolescence built into the technology transfer arrangement.
PUBLICATION DATE: June 11, 2012 PRODUCT #: 712049-HCB-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Levi Strauss & Co.: Global Sourcing (A)
Hebei Dawu Group: Building the First Family Business Constitution in China
Managing Segways Early Development
The Genuine Responsibilities of the CEO: A Framework for Managing Today
IMAX Expansion in BRIC Economies
Negotiations Between Auditors and their Clients Regarding Adjustments to the Financial Statements
DePaul Industries in 2012: Financing Growth in a Social Venture
Preparing for Disruptions Through Early Detection
FC Barcelona: “Més que un club”
Ina Food Industry (2): Marketing Strategies in a Deflationary Environment
